Publications by authors named "Yilan Teng"

Article Synopsis
  • The FDA has approved the first siRNA drug, marking a major advancement in RNA interference technology.
  • Off-target gene silencing remains a challenge in siRNA therapy, raising concerns about unintended effects.
  • A new strategy using AGO2 mutants was developed to identify siRNA off-targets, enhancing our understanding of siRNA interactions and improving design rules for future therapies.
View Article and Find Full Text PDF

UV crosslinking and immunoprecipitation (CLIP) coupled with high-throughput sequencing is the most state-of-the-art technology to characterize protein-RNA interactions, yet only a small portion of RNA-binding proteins (RBPs) have been studied by CLIP due to its complex procedures and high level of false-positive signals. Herein, we report a SpyCLIP method that employs a covalent linkage formed between the RBP-fused SpyTag and SpyCatcher, which can withstand the harshest washing conditions for removing nonspecific interactions. Moreover, SpyCLIP circumvents the radioactive labeling and PAGE-membrane purification steps, and the whole procedure can be performed on beads and is readily amenable to automation.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Yilan Teng"

  • - Yilan Teng's research primarily focuses on advancing RNA interference (RNAi) technologies, particularly in the context of small interfering RNAs (siRNAs) and microRNAs (miRNAs), while addressing challenges related to off-target effects in therapeutic applications.
  • - One of Teng's notable contributions is the development of the SpyCLIP method, which enhances the characterization of protein-RNA interactions with improved accuracy and ease of use compared to traditional CLIP methods, thus making it more accessible for studying RNA-binding proteins.
  • - The findings from Teng's studies highlight both the complexities of unintended gene silencing effects by siRNAs and the innovations in high-throughput techniques for analyzing RNA interactions, which are crucial for better understanding and optimizing RNA-based therapies.